You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 萬泰生物跌5% 二價HPV疫苗對於公司營收影響有限
格隆匯 05-31 10:07
格隆匯5月31日丨萬泰生物(603392.SH)現跌6.36%,報124.36元,總市值1095億元。萬泰生物30日披露股票異動公吿,公司的二價HPV疫苗是首個獲批的國產HPV疫苗,九價HPV疫苗正處於三期臨牀試驗中,公司與GSK合作的新一代HPV疫苗也在積極推進研發中。目前,公司二價HPV疫苗的年產能達3000萬支。公司的二價HPV疫苗自上市以來,主要供應自費市場,各地方政府自主針對特定年齡段免費自願接種的採購量佔比較小,對於公司的營業收入影響有限。公司HPV疫苗的競爭對手除已上市的默沙東、GSK和沃森生物外,另有多個競爭對手的產品處於研發及臨牀試驗中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account